Pain Therapeutics (NASDAQ:PTIE) shares saw strong trading volume on Monday . 100,328 shares traded hands during mid-day trading, an increase of 52% from the previous session’s volume of 66,135 shares.The stock last traded at $2.25 and had previously closed at $2.24.

Separately, Zacks Investment Research cut Pain Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th.

The stock’s market capitalization is $103.82 million. The company’s 50 day moving average is $2.19 and its 200-day moving average is $2.06.

Pain Therapeutics (NASDAQ:PTIE) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.03. Equities analysts predict that Pain Therapeutics will post ($0.57) earnings per share for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.